uniQure NV (QURE)
22.69
-0.02
(-0.11%)
USD |
NASDAQ |
Oct 21, 16:00
24.06
+1.37
(+6.04%)
Pre-Market: 08:13
uniQure Enterprise Value : 1.315B for Oct. 21, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 21, 2026 | 1.315B |
| October 20, 2026 | 1.317B |
| October 19, 2026 | 1.281B |
| October 16, 2026 | 1.252B |
| October 15, 2026 | 1.303B |
| October 14, 2026 | 1.196B |
| October 13, 2026 | 1.217B |
| October 12, 2026 | 1.256B |
| October 09, 2026 | 1.308B |
| October 08, 2026 | 1.305B |
| October 07, 2026 | 1.346B |
| October 06, 2026 | 1.341B |
| October 05, 2026 | 1.323B |
| October 02, 2026 | 1.368B |
| October 01, 2026 | 1.362B |
| September 30, 2026 | 1.417B |
| September 29, 2026 | 1.441B |
| September 28, 2026 | 2.454B |
| September 25, 2026 | 2.393B |
| September 24, 2026 | 2.399B |
| September 23, 2026 | 2.707B |
| September 22, 2026 | 2.881B |
| September 21, 2026 | 2.814B |
| September 18, 2026 | 2.793B |
| September 17, 2026 | 2.799B |
| Date | Value |
|---|---|
| September 16, 2026 | 2.688B |
| September 15, 2026 | 2.730B |
| September 14, 2026 | 2.857B |
| September 11, 2026 | 2.828B |
| September 10, 2026 | 2.825B |
| September 09, 2026 | 2.931B |
| September 08, 2026 | 2.909B |
| September 04, 2026 | 2.827B |
| September 03, 2026 | 2.852B |
| September 02, 2026 | 2.947B |
| September 01, 2026 | 3.060B |
| August 31, 2026 | 3.117B |
| August 28, 2026 | 3.120B |
| August 27, 2026 | 3.178B |
| August 26, 2026 | 3.274B |
| August 25, 2026 | 3.281B |
| August 24, 2026 | 3.032B |
| August 21, 2026 | 3.096B |
| August 20, 2026 | 3.132B |
| August 19, 2026 | 3.123B |
| August 18, 2026 | 3.027B |
| August 17, 2026 | 3.068B |
| August 14, 2026 | 3.113B |
| August 13, 2026 | 3.005B |
| August 12, 2026 | 2.871B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Kymera Therapeutics, Inc. | 8.712B |
| Moderna, Inc. | 94.23B |
| Abivax SA | 7.003B |
| GRAIL, Inc. | 5.152B |
| Arrowhead Pharmaceuticals, Inc. | 8.079B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -81.06M |
| Revenue (Quarterly) | 5.841M |
| Total Expenses (Quarterly) | 86.90M |
| EPS Diluted (Quarterly) | -1.224 |
| Gross Profit Margin (Quarterly) | 10.00% |
| Profit Margin (Quarterly) | -1.39K% |
| Earnings Yield | -17.84% |
| Normalized Earnings Yield | -17.70 |